Received approval of NG101(RY104) for phase 1/2a clinical trials in Canada under co-development with Neuracle Genetics

Signed a joint development agreement with Therabest for NK cell therapy

Completed phase 1 clinical trial in Canada for RY103(NS101) under co-development with Neuracle Science, an ivestigational monoclonal antibody for the treatment of Alzheimer’s disease

Signed an MOU with Protium Science for comprehensive business cooperation for CDMO business

Signed an MOU with Connext for comprehensive business cooperation for CDMO business

Signed an MOU with Therabest for business cooperation to supply pDNA samples

Signed an MOU with T&R Biofab for the joint development and commercializationn of next-generation hemostatic agents

Participated in Bioplus-Interpex Korea 2022 for partnership expansion

Signed an MOU with Aston Science for joint R&D and commercializing a plasmid-DNA cancer treatment vaccine

Signed MOU on Joint R&D for Mass Production of Cellular and Gene Therapy Agents with Samsung Medical Center

Signed First Agreement for Contract Manufacturing of pDNA

Held Completion Ceremony for Chungju Bio and Chemical Plants

Completed Construction of Chungju Chemical Plant and Paves Foundation for Global Pharmaceutical Production Platform

Received Go-Ahead for Phase 1 Clinical Trial on Neuracle Science’s New Antibody Drug for Dementia

Signed MOU with Cellumed for Mass Production of mRNA-producing Enzymes and Development of mRNA Vaccines

Signed Licensing Agreement with iNtRON Biotechnology on Antifungal Drug Candidate

Conducted Joint R&D on Antiviral Vaccine and Rare Genetic Disease Treatment with MDimune

Signed Agreement to Produce and Supply Samples for Efficacy Evaluation of Anti-Fibrotic Gene Therapy

Unveiled New Corporate CI and Opens Upgraded Website

Made a term (MOU) for joint development and commercialization of & PHAGERUS® vaccine and treatment with iNtRON Biotechnology

Entered into an agreement regarding AAV gene therapy with Neuracle Genetics

Entered into an agreement(MOU) on joint development and commercialization for liver fibrosis gene therapy with Neo Gene Pharm

Signed a technology transfer contract for commercialization of PDRN with BNF Solution Co., Ltd.

Secured new candidates for COVID-19 treatment

Signed a business agreement with Interbiome in the United States to establish and operate cGMP manufacturing facilities for virus-based gene therapy products

Acquired ISO 37001 (corruption prevention management system) certification

Selected as the best job provider in Korea (Ministry of Employment and Labor)

Signed a memorandum of understanding for the establishment of a joint venture for commercial production of next-generation CAR-T treatments with CUROCELL.

Awarded an exemplary taxpayer citation (Director of National Tax Service)

Decision made to build chemical pharmaceuticals cGMP plant in Chungju

Declared vision 'BEST till 2023'

Signed investment contract with Neuracle Genetics Co., Ltd.

Signed business agreement with GNP Bioscience for the development of natural medicines and health functional foods

Signed antibody treatment joint development contract with Neuracle Science Co., Ltd.

Signed joint development contract for gene therapy products with GNP Bioscience Co., Ltd.

Signed business agreement for natural drug development with FINZELBERG, Germany

Commenced construction of cGMP plant for gene therapy products in Chungju

Vascular and neurological disease gene therapy drug approved in US for phase 3 (2nd) clinical trial for treatment of diabetic neuropathy

Head office relocated (Yongsan-gu, Seoul → Gangnam-gu, Seoul)

Vascular and neurological disease gene therapy drug approved in Korea for phase 2 clinical trial for treatment of amyotrophic lateral sclerosis (ALS)

Vascular and neurological disease gene therapy drug approved for phase 2 clinical trial for treatment of coronary artery disease (CAD) in Korea

Vascular and neurological disease gene therapy designated for fast track development for treatment of amyotrophic lateral sclerosis (ALS) by the US Food and Drug Administration

Vascular and neurological disease gene therapy drug approved for phase 3 clinical trial for treatment of chronic non-healing diabetic/ischemic ulcers (NHU)

Vascular and neurological disease gene therapy drug approved for phase 3 (1st) of clinical trial for treatment of diabetic neuropathy in US

Vascular and neurological disease gene therapy drug phase 2 clinical trial for treatment of diabetic neuropathy in completed US/Korea

Acquired site for Chungju Bio/Chemical cGMP plant

Vascular and neurological disease gene therapy drug phase 2 clinical trial for treatment of critical limb ischemia (CLI) approved in US/Korea

Vascular and neurological disease gene therapy approved as orphan drug for treatment of amyotrophic lateral sclerosis (ALS) the US Food and Drug Administration

Completed phase 1 clinical trial (breast cancer) in Korea for anticancer gene therapy

Signed global commercialization joint development contract with ViroMed Co., Ltd. for vascular and neurological disease gene therapy drug for treating amyotrophic lateral sclerosis (ALS)

Concluded contract for exporting antibiotic arbekacin sulfate to Russia

Concluded technology and worldwide sales rights transfer contract with ViroMed for chronic hepatitis B DNA vaccine

Concluded contract to export antibiotic arbekacin sulfate product/raw materials to China

Presented KRW 100 Billion Venture Business Award (Small and Medium Business Administration, Korea Venture Business Association)

Concluded contract for exporting antibiotic arbekacin sulfate to India

Listed on Korea Stock Exchange

Central Research Center relocated (Dongbinggo-dong, Yongsan-gu, Seoul → Pyeongchon-dong, Dongan-gu, Anyang-si)

Awarded model taxpayer citation (Minister of Strategy and Finance)

Signed anticancer gene therapy joint development contract with ViroMed Co., Ltd.

Signed joint development contract with ViroMed Co., Ltd. for vascular and neurological disease gene therapy drug

Selected as an INNOBIZ company (Small and Medium Business Administration)

Selected as an excellent technology company (Korea Technology Finance Corporation)

Developed Teicoplanin as a first generic API

Became the first company in Korea to release Arbekacin sulfate, which is specially effective against MRSA

Introduced original contrast agent (Optiray) product

Synthesized antibiotic Arbekacin sulfate as a first generic manufacturer, and commenced export to Japan

Completion of fermentation plant (located in Deoksan-eup, Jincheon-gun, Chungcheongbuk-do, Korea)

Changed the company name from REYON Synthetics Co., Ltd. to REYON Pharmaceutical Co., Ltd.

Completed construction of Jincheon Factory (located in Deoksan-eup, Jincheon-gun, Chungcheongbuk-do, Korea)

Established affiliated REYON Central Research Center

Joint development of Streptokinase,streptodornase (SKD) manufacturing technology (KIST)

Incorporated as REYON Synthetics Co., Ltd.

Established REYON Research Center